ストックスクリーナーアプリを入手
27.65
0.61%
-0.17
アフターアワーズ：
27.40
-0.25
-0.90%
前日終値:
$27.82
開ける：
$28.08
24時間の取引高:
1.49M
Relative Volume:
1.30
時価総額：
$2.29B
収益：
$352.57M
当期純損益:
$-143.01M
株価収益率:
-15.28
EPS:
-1.81
ネットキャッシュフロー:
$-153.40M
1週間 パフォーマンス:
+1.36%
1か月 パフォーマンス:
+4.89%
6か月 パフォーマンス:
+8.35%
1年 パフォーマンス:
-0.82%
1日の値動き範囲:
$27.52
$28.95
1週間の範囲:
$24.32
$28.95
52週間の値動き範囲:
$20.84
$49.50
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.65 | 2.29B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Beam Therapeutics (NASDAQ:BEAM) Shares Up 8%Still a Buy? - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $802,500.00 in Stock - MarketBeat
What is HC Wainwright's Estimate for BEAM FY2026 Earnings? - MarketBeat
(BEAM) Long Term Investment Analysis - Stock Traders Daily
Brokers Set Expectations for BEAM Q1 Earnings - MarketBeat
H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com India
H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com Australia
HC Wainwright Reaffirms "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpWhat's Next? - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for BEAM Earnings - MarketBeat
Top 5 CRISPR Companies To Invest In (February 2025) - Securities.io
(BEAM)Analyzing Beam Therapeutics's Short Interest - Benzinga
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares - Simply Wall St
Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week - Yahoo Finance
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Cantor Fitzgerald Upgrades Beam Therapeutics (BEAM) - MSN
Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Beam Therapeutics (NASDAQ:BEAM) Raised to "Overweight" at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral -January 29, 2025 at 07:29 am EST - Marketscreener.com
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet - Yahoo Finance
Is it a Good Idea to Invest in Beam Therapeutics Stock Now? - MSN
Leerink Partnrs Issues Optimistic Forecast for BEAM Earnings - Defense World
(BEAM) Investment Report - Stock Traders Daily
FY2024 Earnings Estimate for BEAM Issued By Leerink Partnrs - MarketBeat
Cantor Fitzgerald Predicts BEAM FY2025 Earnings - Defense World
Research Analysts Issue Forecasts for BEAM FY2025 Earnings - MarketBeat
Beam Therapeutics to present updated BEAM-101 trial data - Investing.com India
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR - The Manila Times
Beam Therapeutics to present updated BEAM-101 trial data By Investing.com - Investing.com UK
Beam Therapeutics to Encore Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics' BEAM-101 Shows Strong Results in Sickle Cell Disease Trial Data - StockTitan
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Beam Therapeutics Shares Cross Above 200 DMA - Nasdaq
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts - Seeking Alpha
50,285 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Bought by Avanza Fonder AB - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Beam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestones - MSN
Beam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestones By Investing.com - Investing.com South Africa
Beam Therapeutics (NASDAQ:BEAM) Shares Down 8%Should You Sell? - MarketBeat
Beam Therapeutics’ (BEAM) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Beam Therapeutics (NASDAQ:BEAM) Given Outperform Rating at Wedbush - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Trading Down 8%Time to Sell? - MarketBeat
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now? - MSN
Beam Therapeutics advances gene editing trials, eyes mid-2025 updates By Investing.com - Investing.com South Africa
Beam Therapeutics advances gene editing trials, eyes mid-2025 updates - Investing.com India
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
0.53%
大文字化:
|
ボリューム (24 時間):